An Open-label, Multicenter, Randomized Phase 3 Study of First-line Encorafenib Plus Cetuximab With or Without Chemotherapy Versus Standard of Care Therapy with A Safety Lead-in of Encorafenib And Cetuximab Plus Chemotherapy in Participants with Metastatic BRAF V600E-Mutant Colorectal Cancer (NCT04607421)
BREAKWATER
This trial is No longer recruiting
Registration number NCT04607421
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Ben Markman
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.